Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation

Science Translational Medicine

Volumn 11, Issue 486, 2019, Pages

  Bourke, Claire D ^a   Gough, Ethan K ^m   Pimundu, Godfrey ^c   Shonhai, Annie ^d   Berejena, Chipo ^d   Terry, Louise ^e   Baumard, Lucas ^a   Choudhry, Naheed ^a   Karmali, Yusuf ^a   Bwakura Dangarembizi, Mutsa ^d   Musiime, Victor ^c,f   Lutaakome, Joseph ^g   Kekitiinwa, Adeodata ^h   Mutasa, Kuda ⁱ   Szubert, Alexander J ^j   Spyer, Moira J ^j   Deayton, Jane R ^a,e   Glass, Magdalena ^b,n   Geum, Hyun Min ^b   Pardieu, Claire ^a   Gibb, Diana M ^j   Klein, Nigel ^k   Edens, Thaddeus J ^l   Sarah Walker, A ^j   Manges, Amee R ^b   Prendergast, Andrew J ^a,i   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

^f MAKERERE UNIVERSITY   (Uganda)

^g UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^h MULAGO HOSPITAL   (Uganda)

ⁱ Zvitambo Institute for Maternal and Child Health Research   (Zimbabwe)

^j MRC CLINICAL TRIALS UNIT   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l Devil's Staircase Consulting   (Canada)

^m JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

ⁿ CANADA'S MICHAEL SMITH GENOME SCIENCES CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; COTRIMOXAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERLEUKIN 6; INTERLEUKIN 8; MEVALONIC ACID; MYELOPEROXIDASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR; AUTACOID; CYTOKINE;

ALISTIPES; ALISTIPES ONDERDONKII; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CELL SUBPOPULATION; CLINICAL ARTICLE; CLOSTRIDIUM; CLOSTRIDIUM BARTLETTI; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EGGERTHELLA LENTA; ENTERITIS; EPITHELIUM CELL; HAEMOPHILUS PARAINFLUENZAE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INTESTINE FLORA; LYMPHOCYTE PROLIFERATION; MALNUTRITION; METAGENOME; MICROBIAL COMMUNITY; MORTALITY; NONHUMAN; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PHENOTYPE; POPULATION ABUNDANCE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECIES DIVERSITY; STREPTOCOCCUS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS PARASANGUINIS; STREPTOCOCCUS SALIVARIUS; T LYMPHOCYTE; TREATMENT OUTCOME; UGANDAN; ZIMBABWE; CHILD; CONTROLLED STUDY; DRUG EFFECT; IMMUNOLOGY; INFLAMMATION; INTESTINE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYTOKINES; DISEASE PROGRESSION; EPITHELIAL CELLS; GASTROINTESTINAL MICROBIOME; HIV INFECTIONS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTESTINES; NUTRITIONAL STATUS; PHENOTYPE; STREPTOCOCCUS; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 85064162062     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aav0537     Document Type: Article

References (68)

1. UNAIDS, Fact sheet - Latest global and regional statistics on the status of the AIDS epidemic - July 2018. (2018).
2. J. A. Church, F. Fitzgerald, A. S. Walker, D. M. Gibb, A. J. Prendergast, The expanding role of co-trimoxazole in developing countries. Lancet Infect. Dis. 15, 327–339 (2015).
3. A. S. Walker, D. Ford, C. F. Gilks, P. Munderi, F. Ssali, A. Reid, E. Katabira, H. Grosskurth, P. Mugyenyi, J. Hakim, J. H. Darbyshire, D. M. Gibb, A. G. Babiker, Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: An observational analysis of the DART cohort. Lancet 375, 1278–1286 (2010).
4. WHO, Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: Recommendations for a public health approach - December 2014 supplement to the 2013 consolidated ARV guidelines (WHO Press, 2014), pp. 49.
5. A. J. Prendergast, A. J. Szubert, C. Berejena, G. Pimundu, P. Pala, A. Shonhai, V. Musiime, M. Bwakura-Dangarembizi, H. Poulsom, P. Hunter, P. Musoke, M. Kihembo, P. Munderi, D. M. Gibb, M. Spyer, A. S. Walker, N. Klein, ARROW Trial Team, Baseline inflammatory biomarkers identify subgroups of HIV-infected African children with differing responses to antiretroviral therapy. J. Infect. Dis. 214, 226–236 (2016).
6. L. H. Kuller, R. Tracy, W. Belloso, S. D. Wit, F. Drummond, H. C. Lane, B. Ledergerber, J. Lundgren, J. Neuhaus, D. Nixon, N. I. Paton, J. D. Neaton, for the INSIGHT SMART Study Group, Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLOS Med. 5, e203 (2008).
7. N. G. Sandler, H. Wand, A. Roque, M. Law, M. C. Nason, D. E. Nixon, C. Pedersen, K. Ruxrungtham, S. R. Lewin, S. Emery, J. D. Neaton, J. M. Brenchley, S. G. Deeks, I. Sereti, D. C. Douek, INSIGHT SMART Study Group, Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203, 780–790 (2011).
8. J. H. Campbell, T. H. Burdo, P. Autissier, J. P. Bombardier, S. V. Westmoreland, C. Soulas, R. G. González, E.-M. Ratai, K. C. Williams, Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV NeuroAIDS. PLOS ONE 6, e18688 (2011).
9. J. Vesterbacka, P. Nowak, B. Barqasho, S. Abdurahman, J. Nyström, S. Nilsson, H. Funaoka, T. Kanda, L.-M. Andersson, M. Gisslèn, A. Sönnerborg, Kinetics of microbial translocation markers in patients on Efavirenz or Lopinavir/r based antiretroviral therapy. PLOS ONE 8, e55038 (2013).
10. J. Vesterbacka, B. Barqasho, A. Haggblom, P. Nowak, Effects of co-trimoxazole on microbial translocation in HIV-1-infected patients initiating antiretroviral therapy. AIDS Res. Hum. Retrovir. 31, 830–836 (2015).
11. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200, 749–759 (2004).
12. + T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J. Clin. Investig. 122, 62–69 (2012).
13. K. Allers, M. Fehr, K. Conrad, H.-J. Epple, D. Schürmann, A. Geelhaar-Karsch, K. Schinnerling, V. Moos, T. Schneider, Macrophages accumulate in the gut mucosa of untreated HIV-infected patients. J. Infect. Dis. 209, 739–748 (2013).
14. M. Somsouk, J. D. Estes, C. Deleage, R. M. Dunham, R. Albright, J. M. Inadomi, J. N. Martin, S. G. Deeks, J. M. McCune, P. W. Hunt, Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS 29, 43–51 (2015).
15. J. M. Brenchley, D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S. Rao, Z. Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, B. R. Blazar, B. Rodriguez, L. Teixeira-Johnson, A. Landay, J. N. Martin, F. M. Hecht, L. J. Picker, M. M. Lederman, S. G. Deeks, D. C. Douek, Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365–1371 (2006).
16. A. P. Kourtis, C. C. Ibegbu, J. Wiener, C. C. King, G. Tegha, D. Kamwendo, J. Kumwenda, S. P. Kaur, V. Flax, S. Ellington, Z. Kacheche, D. Kayira, C. Chasela, C. van der Horst, D. J. Jamieson, Role of intestinal mucosal integrity in HIV transmission to infants through breast-feeding: The BAN study. J. Infect. Dis. 208, 653–661 (2013).
17. C. A. Lozupone, M. Li, T. B. Campbell, S. C. Flores, D. Linderman, M. J. Gebert, R. Knight, A. P. Fontenot, B. E. Palmer, Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe 14, 329–339 (2013).
18. S. M. Dillon, E. J. Lee, C. V. Kotter, G. L. Austin, Z. Dong, D. K. Hecht, S. Gianella, B. Siewe, D. M. Smith, A. L. Landay, C. E. Robertson, D. N. Frank, C. C. Wilson, An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 7, 983–994 (2014).
19. F. Dossou-Yovo, G. Mamadou, I. D. Soudy, N. Limas-Nzouzi, J. Miantezila, J.-F. Desjeux, B. Eto, Metronidazole or cotrimoxazole therapy is associated with a decrease in intestinal bioavailability of common antiretroviral drugs. PLOS ONE 9, e89943 (2014).
20. I. Pandrea, C. Xu, J. L. Stock, D. N. Frank, D. Ma, B. B. Policicchio, T. He, J. Kristoff, E. Cornell, G. S. Haret-Richter, A. Trichel, R. M. Ribeiro, R. Tracy, C. Wilson, A. L. Landay, C. Apetrei, Antibiotic and anti-inflammatory therapy transiently reduces inflammation and hypercoagulation in acutely SIV-infected pigtailed macaques. PLOS Pathog. 12, e1005384 (2016).
21. C. L. Monaco, D. B. Gootenberg, G. Zhao, S. A. Handley, M. S. Ghebremichael, E. S. Lim, A. Lankowski, M. T. Baldridge, C. B. Wilen, M. Flagg, J. M. Norman, B. C. Keller, J. M. Luévano, D. Wang, Y. Boum, J. N. Martin, P. W. Hunt, D. R. Bangsberg, M. J. Siedner, D. S. Kwon, H. W. Virgin, Altered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunodeficiency syndrome. Cell Host Microbe 19, 311–322 (2016).
22. M. W. Ghilchik, A. S. Morris, D. S. Reeves, Immunosuppressive powers of the antibacterial agent trimethoprim. Nature 227, 393–394 (1970).
23. R. Anderson, G. Grabow, R. Oosthuizen, A. Theron, A. J. Van Rensburg, Effects of sulfamethoxazole and trimethoprim on human neutrophil and lymphocyte functions in vitro: In vivo effects of co-trimoxazole. Antimicrob. Agents Chemother. 17, 322–326 (1980).
24. O. Pos, A. Stevenhagen, P. L. Meenhorst, F. P. Kroon, R. Van Furth, Impaired phagocytosis of Staphylococcus aureus by granulocytes and monocytes of AIDS patients. Clin. Exp. Immunol. 88, 23–28 (1992).
25. N. M. Wolfish, N. Wassef, H. Gonzalez, C. Acharya, Immunologic parameters of children with urinary tract infection: Effects of trimethoprim-sulfamethoxazole. Can. Med. Assoc. J. 112, 76–79 (1975).
26. P. M. Gaylarde, I. Sarkany, Suppression of thymidine uptake of human lymphocytes by co-trimoxazole. Br. Med. J. 3, 144–146 (1972).
27. M. Bwakura-Dangarembizi, L. Kendall, S. Bakeera-Kitaka, P. Nahirya-Ntege, R. Keishanyu, K. Nathoo, M. J. Spyer, A. Kekitiinwa, J. Lutaakome, T. Mhute, P. Kasirye, P. Munderi, V. Musiime, D. M. Gibb, A. S. Walker, A. J. Prendergast, A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N. Engl. J. Med. 370, 41–53 (2014).
28. E. K. Gough, E. E. M. Moodie, A. J. Prendergast, S. M. A. Johnson, J. H. Humphrey, R. J. Stoltzfus, A. S. Walker, I. Trehan, D. M. Gibb, R. Goto, S. Tahan, M. B. de Morais, A. R. Manges, The impact of antibiotics on growth in children in low and middle income countries: Systematic review and meta-analysis of randomised controlled trials. Br. Med. J. 348, g2267 (2014).
29. A. Prendergast, A. S. Walker, V. Mulenga, C. Chintu, D. M. Gibb, Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis. Clin. Infect. Dis. 52, 953–956 (2011).
30. J. V. Giorgi, L. E. Hultin, J. A. McKeating, T. D. Johnson, B. Owens, L. P. Jacobson, R. Shih, J. Lewis, D. J. Wiley, J. P. Phair, S. M. Wolinsky, R. Detels, Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179, 859–870 (1999).
31. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16, 83–92 (1997).
32. + T-cells or T-cells, in HIV patients responding to ART. Immunol. Cell Biol. 88, 321–327 (2010).
33. C. P. Neff, O. Krueger, K. Xiong, S. Arif, N. Nusbacher, J. M. Schneider, A. W. Cunningham, A. Armstrong, S. Li, M. D. McCarter, T. B. Campbell, C. A. Lozupone, B. E. Palmer, Fecal microbiota composition drives immune activation in HIV-infected individuals. EBioMedicine 30, 192–202 (2018).
34. K. M. Powis, S. Souda, S. Lockman, G. Ajibola, K. Bennett, J. Leidner, M. D. Hughes, S. Moyo, E. van Widenfelt, H. B. Jibril, J. Makhema, M. Essex, R. L. Shapiro, Cotrimoxazole prophylaxis was associated with enteric commensal bacterial resistance among HIV-exposed infants in a randomized controlled trial, Botswana. J. Int. AIDS Soc. 20, e25021 (2017).
35. J. Mwansa, K. Mutela, I. Zulu, B. Amadi, P. Kelly, Antimicrobial sensitivity in enterobacteria from AIDS patients, Zambia. Emerg. Infect. Dis. 8, 92–93 (2002).
36. M. Scholz, D. V. Ward, E. Pasolli, T. Tolio, M. Zolfo, F. Asnicar, D. T. Truong, A. Tett, A. L. Morrow, N. Segata, Strain-level microbial epidemiology and population genomics from shotgun metagenomics. Nat. Methods 13, 435–438 (2016).
37. D. Lau, H. Mollnau, J. P. Eiserich, B. A. Freeman, A. Daiber, U. M. Gehling, J. Brümmer, V. Rudolph, T. Münzel, T. Heitzer, T. Meinertz, S. Baldus, Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc. Natl. Acad. Sci. U.S.A. 102, 431–436 (2005).
38. T. W. Chin, A. Vandenbroucke, I. W. Fong, Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob. Agents Chemother. 39, 28–33 (1995).
39. N. T. Funderburg, Y. Jiang, S. M. Debanne, D. Labbato, S. Juchnowski, B. Ferrari, B. Clagett, J. Robinson, M. M. Lederman, G. A. McComsey, Rosuvastatin reduces vascular inflammation and T cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 68, 396–404 (2015).
40. N. I. Paton, R. L. Goodall, D. T. Dunn, S. Franzen, Y. Collaco-Moraes, B. G. Gazzard, I. G. Williams, M. J. Fisher, A. Winston, J. Fox, C. Orkin, E. A. Herieka, J. G. Ainsworth, F. A. Post, M. Wansbrough-Jones, P. Kelleher, Hydroxychloroquine Trial Team, Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: A randomized controlled trial. JAMA 308, 353–361 (2012).
41. J.-P. Routy, J. B. Angel, M. Patel, C. Kanagaratham, D. Radzioch, I. Kema, N. Gilmore, P. Ancuta, J. Singer, M.-A. Jenabian, Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 16, 48–56 (2015).
42. R. D. Moore, J. G. Bartlett, J. E. Gallant, Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLOS ONE 6, e21843 (2011).
43. WHO, UNAIDS, Unicef, Global HIV/AIDS response: Epidemic update and health sector progress towards universal access (WHO Press, 2011).
44. P. W. Hunt, S. A. Lee, M. J. Siedner, Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J. Infect. Dis. 214, S44–S50 (2016).
45. + T-cell pool in healthy children and untreated children infected with HIV-1. Blood 104, 3513–3519 (2004).
46. C. D. Doern, C.-A. D. Burnham, It's not easy being green: The viridans group streptococci, with a focus on pediatric clinical manifestations. J. Clin. Microbiol. 48, 3829–3835 (2010).
47. B. Van den Bogert, J. Boekhorst, R. Herrmann, E. J. Smid, E. G. Zoetendal, M. Kleerebezem, Comparative genomics analysis of Streptococcus isolates from the human small intestine reveals their adaptation to a highly dynamic ecosystem. PLOS ONE 8, e83418 (2014).
48. G. Li, M. Yang, K. Zhou, L. Zhang, L. Tian, S. Lv, Y. Jin, W. Qian, H. Xiong, R. Lin, Y. Fu, X. Hou, Diversity of duodenal and rectal microbiota in biopsy tissues and luminal contents in healthy volunteers. J. Microbiol. Biotechnol. 25, 1136–1145 (2015).
49. P. Vonaesch, E. Morien, L. Andrianonimiadana, H. Sanke, J.-R. Mbecko, K. E. Huus, T. Naharimanananirina, B. P. Gondje, S. N. Nigatoloum, S. S. Vondo, J. E. Kaleb Kandou, R. Randremanana, M. Rakotondrainipiana, F. Mazel, S. G. Djorie, J.-C. Gody, B. B. Finlay, P.-A. Rubbo, L. Wegener Parfrey, J.-M. Collard, P. J. Sansonetti, The Afribiota Investigators, Stunted childhood growth is associated with decompartmentalization of the gastrointestinal tract and overgrowth of oropharyngeal taxa. Proc. Natl. Acad. Sci. U.S.A. 115, E8489–E8498 (2018).
50. A. J. Prendergast, S. Rukobo, B. Chasekwa, K. Mutasa, R. Ntozini, M. N. N. Mbuya, A. Jones, L. H. Moulton, R. J. Stoltzfus, J. H. Humphrey, Stunting is characterized by chronic inflammation in Zimbabwean infants. PLOS ONE 9, e86928 (2014).
51. B. van den Bogert, M. Meijerink, E. G. Zoetendal, J. M. Wells, M. Kleerebezem, Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota. PLOS ONE 9, e114277 (2014).
52. K. M. Harper, M. Mutasa, A. J. Prendergast, J. Humphrey, A. R. Manges, Environmental enteric dysfunction pathways and child stunting: A systematic review. PLOS Negl. Trop. Dis. 12, e0006205 (2018).
53. A. M. Ortiz, J. K. Flynn, S. R. DiNapoli, I. Vujkovic-Cvijin, C. E. Starke, S. H. Lai, M. E. Long, O. Sortino, C. L. Vinton, J. C. Mudd, L. Johnston, K. Busman-Sahay, Y. Belkaid, J. D. Estes, J. M. Brenchley, Experimental microbial dysbiosis does not promote disease progression in SIV-infected macaques. Nat. Med. 24, 1313–1316 (2018).
54. S. Heuston, M. Begley, C. G. M. Gahan, C. Hill, Isoprenoid biosynthesis in bacterial pathogens. Microbiology 158, 1389–1401 (2012).
55. M. A. Elmore, R. H. Daniels, M. E. Hill, M. J. Finnen, Inhibition of neutrophil priming by inhibitors of farnesyl transferase. Biochem. Soc. Trans. 25, 253S (1997).
56. R. Terkeltaub, J. Solan, M. Barry Jr., D. Santoro, G. M. Bokoch, Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J. Leukoc. Biol. 55, 749–755 (1994).
57. E. Furrie, S. Macfarlane, G. Thomson, G. T. Macfarlane, Microbiology & Gut Biology Group, Tayside Tissue & Tumour Bank, Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 115, 565–574 (2005).
58. J. D. Keenan, R. L. Bailey, S. K. West, A. M. Arzika, J. Hart, J. Weaver, K. Kalua, Z. Mrango, K. J. Ray, C. Cook, E. Lebas, K. S. O'Brien, P. M. Emerson, T. C. Porco, T. M. Lietman, MORDOR Study Group, Azithromycin to reduce childhood mortality in sub-Saharan Africa. N. Engl. J. Med. 378, 1583–1592 (2018).
59. ARROW Trial team, A. Kekitiinwa, A. Cook, K. Nathoo, P. Mugyenyi, P. Nahirya-Ntege, S. Bakeera-Kitaka, M. Thomason, M. Bwakura-Dangarembizi, V. Musiime, P. Munderi, B. Naidoo-James, T. Vhembo, C. Tumusiime, R. Katuramu, J. Crawley, A. J. Prendergast, P. Musoke, A. S. Walker, D. M. Gibb, Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): A 5-year open-label randomised factorial trial. Lancet 381, 1391–1403 (2013).
60. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B. Methodol. 57, 289–300 (1995).
61. P. Dixon, M. W. Palmer, VEGAN, a package of R functions for community ecology. J. Veg. Sci. 14, 927–930 (2003).
62. R. A. Rigby, D. M. Stasinopoulos, Generalized additive models for location, scale and shape. J. R. Stat. Soc.: Ser. C: Appl. Stat. 54, 507–554 (2005).
63. J. D. Kloke, J. W. McKean, Rfit: Rank-based estimation for linear models. R Journal 4, 57–64 (2012).
64. WHO, Antiretroviral therapy for HIV infection in infants and children: Towards universal access: Recommendations for a public health approach (2006).
65. M. Bwakura-Dangarembizi, V. Musiime, A. J. Szubert, A. J. Prendergast, Z. A. Gomo, M. J. Thomason, C. Musarurwa, P. Mugyenyi, P. Nahirya, A. Kekitiinwa, D. M. Gibb, A. S. Walker, K. Nathoo, ARROW Trial Team, Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Pediatr. Infect. Dis. J. 34, e23–e31 (2015).
66. D. T. Truong, E. A. Franzosa, T. L. Tickle, M. Scholz, G. Weingart, E. Pasolli, A. Tett, C. Huttenhower, N. Segata, MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat. Methods 12, 902–903 (2015).
67. S. Abubucker, N. Segata, J. Goll, A. M. Schubert, J. Izard, B. L. Cantarel, B. Rodriguez-Mueller, J. Zucker, M. Thiagarajan, B. Henrissat, O. White, S. T. Kelley, B. Methé, P. D. Schloss, D. Gevers, M. Mitreva, C. Huttenhower, Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLOS Comput. Biol. 8, e1002358 (2012).
68. R. D. Finn, A. Bateman, J. Clements, P. Coggill, R. Y. Eberhardt, S. R. Eddy, A. Heger, K. Hetherington, L. Holm, J. Mistry, E. L. L. Sonnhammer, J. Tate, M. Punta, Pfam: The protein families database. Nucleic Acids Res. 42, D222–D230 (2013).